Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + capecitabine + oxaliplatin
- Development stage
- Phase 3
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Camrelizumab + capecitabine + oxaliplatin is a combination regimen used primarily as first-line therapy for advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Camrelizumab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance antitumor immune responses. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), a pyrimidine analog that inhibits DNA synthesis in rapidly dividing cells. Oxaliplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in cancer cells. The combination leverages immunotherapy with cytotoxic chemotherapy to improve response rates and survival outcomes in patients with advanced G/GEJ adenocarcinoma[2][8][1]. Clinical studies have shown this regimen achieves promising objective response rates and manageable toxicity profiles.
- Brand names
- AiRuiKa
- Other names
- CAPOX plus camrelizumabcamrelizumab combined with CAPOX
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on camrelizumab + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + capecitabine + oxaliplatin.